Avastin Fails Clinical Trial for Prostate Cancer

The New York Times

ZURICH (Reuters) — Roche Holding, the Swiss pharmaceutical giant, said Friday that its cancer drug Avastin did not help men with late-stage prostate cancer live longer in a clinical trial, another setback as the company tries to extend use of the blockbuster drug into new areas.

The miss in prostrate cancer, announced on Friday, follows a similar disappointment last month with Avastin in gastric cancer but success in ovarian cancer... read more